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Quantitation of glucose uptake in tumors by
dynamic FDG-PET has less glucose bias and lower
variability when adjusted for partial saturation of
glucose transport
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Abstract
Background: A retrospective analysis of estimates of tumor glucose uptake from 1,192 dynamic 2-deoxy-2-(18F)
fluoro-D-glucose-positron-emission tomography [FDG-PET] scans showed strong correlations between blood
glucose and both the uptake rate constant [Ki] and the metabolic rate of glucose [MRGluc], hindering the
interpretation of PET scans acquired under conditions of altered blood glucose. We sought a method to reduce
this glucose bias without increasing the between-subject or test-retest variability and did this by considering that
tissue glucose transport is a saturable yet unsaturated process best described as a nonlinear function of glucose
levels.
Methods: Patlak-Gjedde analysis was used to compute Ki from 30-min dynamic PET scans in tumor-bearing mice.
MRGluc was calculated by factoring in the blood glucose level and a lumped constant equal to unity. Alternatively,
we assumed that glucose consumption is saturable according to Michaelis-Menten kinetics and estimated a
hypothetical maximum rate of glucose consumption [MRGlucMAX] by multiplying Ki and (KM + [glucose]), where KM
is a half-saturation Michaelis constant for glucose uptake. Results were computed for 112 separate studies of 8 to
12 scans each; test-retest statistics were measured in a suitable subset of 201 mice.
Results: A KM value of 130 mg/dL was determined from the data based on minimizing the average correlation
between blood glucose and the uptake metric. Using MRGlucMAX resulted in the following benefits compared to
using MRGluc: (1) the median correlation with blood glucose was practically zero, and yet (2) the test-retest
coefficient of variation [COV] was reduced by 13.4%, and (3) the between-animal COVs were reduced by15.5%. In
statistically equivalent terms, achieving the same reduction in between-animal COV while using the traditional
MRGluc would require a 40% increase in sample size.
Conclusions: MRGluc appeared to overcorrect tumor FDG data for changing glucose levels. Applying partial
saturation correction using MRGlucMAX offered reduced bias, reduced variability, and potentially increased statistical
power. We recommend further investigation of MRGlucMAX in quantitative studies of tumor FDG uptake.
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Background
We considered 2-deoxy-2-(18F)fluoro-D-glucose-posi-
tron-emission tomography [FDG-PET] as a pharmaco-
dynamic marker of antitumor activity during treatments
that alter systemic blood glucose levels, for example the
Akt inhibitors [1], and sought a metric of tumor glucose
uptake that had minimal glucose bias. Inverse correla-
tions of blood glucose with tumor FDG uptake have
been demonstrated in multiple settings (see Figures 1
and 2, [2-6]), and this effect was to be expected based
on the biochemistry of glucose (and tracer) transport
and trapping [7].
We undertook a large series of tumor imaging studies
in mice using the metabolic rate of glucose [MRGluc]
from Patlak analysis as our preferred estimate of the
tumor glucose uptake rate, expecting it to be relatively
unbiased with respect to blood glucose. When we
undertook a retrospective review of 1,192 such scans
performed in study groups of 8 to 12 mice, we observed
that our MRGluc data were, in fact, strongly correlated
with blood glucose even though individual studies were
often underpowered to convincingly show this (see Fig-
ure 2B).
We presumed that this correlation caused additional
variability in the uptake measurements. Even in the
absence of any active treatment, blood glucose levels
were not entirely constant in our studies (see Figure 3),
so we sought to apply a rational glucose correction to
the MRGluc data, noting that the bias reduction benefit
must outweigh the cost of the statistical noise intro-
duced by the blood glucose measurements [8].
The original formulations of quantitative glucose
uptake measurements using radioactive uptake assays
were described comprehensively 35 years ago in the
seminal work of Sokoloff et al. [7]. The importance of
glucose transport processes based on saturable Michae-
lis-Menten kinetics has been demonstrated in biochem-
ical studies of glucose transporter 1 [GLUT-1], the
dominant glucose transporter in tumors (and erythro-
cytes and the blood-brain barrier), which have shown
that glucose transport into cells can be characterized as
a saturable process with a half-maximal-rate Michaelis
constant [KM] of approximately 40 mg/dL [9]; it is the
transport step that dominates the overall uptake and
trapping rate in many situations [10,11]. Studies in
intact animals suggested that the apparent half-satura-
tion constant, KM, for the GLUT-1-dominated blood-to-
brain tissue transport was approximately 5 [12] to 7.3
mM [13], equivalent to 100 to 130 mg/dL.
We reasoned that tissue glucose levels are often
neither far below KM (where the glucose transport rate
would be approximately proportional to blood glucose
level) nor far above KM (where the glucose transport
rate would be saturated and independent of blood glu-
cose level). Consequently, tissue glucose uptake rates are
likely to show an intermediate, nonlinear dependence on
blood glucose levels.
We tested this hypothesis using a form of the MRGluc
calculation that employs the Michaelis-Menten relation-
ship to compute the hypothetical maximal uptake rate
[MRGlucMAX] based on an empirical half-saturation KM
of 130 mg/dL (see ‘Results’ section). This approach
should reflect the relatively constant glucose uptake
capacity of the tissue rather than the instantaneous
uptake rate, more or less independent of variations in
blood glucose. We refer to this glucose correction
method as partial saturation correction.
In this paper, we review 112 separate tumor studies of
8 to 12 dynamic FDG scans each, all analyzed with the
Patlak-Gjedde simplified tracer kinetic modeling meth-
ods [14-17] yielding the uptake rate constant [Ki] (per
second) and the MRGluc (in micromoles per minute per
100 cm3). We compared the glucose bias, test-retest,




The data retrospectively analyzed here came from 11
different xenograft models of human cancers that we
have employed in recent projects. Each model is a
unique combination of a mouse strain and a tumor line.
Included were (1) scans from mice studied at baseline
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Figure 1 Relationship between blood glucose concentrations
and FDG-PET metrics in two studies. (A) Ki (red), the tracer
uptake rate constant from Patlak analysis. (B) MRGluc (blue), the
product of Ki and blood glucose. The lines represent the linear
regression fit to the data.
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prior to any treatment and (2) any subsequent scans
from mice enrolled in control groups not receiving any
drug substance. Table 1 describes the 585 mice and
1,192 scans that were included. The mice were studied
as cohorts of 8 to 12 individuals. Each member of a
cohort had the same gender, age, strain, and tumor
type, and they were raised and inoculated at the same
time. The average tumor volume in a cohort was 250 to
400 mm3 at the beginning of an imaging experiment. A
study is defined here as the imaging of one cohort at
one timepoint.
Imaging
All studies were conducted with the approval of Genen-
tech’s AALAC-accredited institutional animal care and
use committee. Briefly, animals were fasted overnight
with free access to water prior to PET imaging. Sevo-
flurane in air [18] was used to induce and maintain
anesthesia sufficient to restrain the animals while they
were scanned prone on the bed of an Inveon MM scan-
ner (Siemens Preclinical Solutions, Knoxville, TN, USA).
PET scans lasted 30 min. X-ray CT scans provided
attenuation correction. List mode data were typically























































































































































































































































































































































































































































FaDu in C.B−17 scid
Figure 3 Individual mouse blood glucose levels (y-axis) on
multiple scanning days (x-axis). Mean scan-time glucose was
calculated as the average of the pre-scan and post-scan
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MRGlucMAX vs Glucose
Figure 2 Pearson’s correlation coefficients between blood glucose and Ki (A), MRGluc (B), and MRGluc
MAX (C). The y-axis represents
Pearson’s correlation value obtained in 112 studies (1,192 observations-see ‘Materials and methods’ section). The x-axis indicates the 11 tumor
models (see Table 1). Open circles represent correlation coefficients of individual studies. Box plots show the 25th, 50th, and 75th percentiles of
correlation coefficient distributions for every animal model. The thick brown dashed lines show the median for all data.
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voxels of 0.4 × 0.4 mm and 0.8 mm through-plane voxel
thickness using vendor-provided iterative OP-MAP
implementation with the beta hyperparameter set to
0.05 [19]. The resolution (approximately 1.5 mm), sensi-
tivity, and other performance characteristics of this
scanner have been described previously [20]. Body tem-
perature was maintained at 37°C by warm air flows
under feedback control. When animals were re-scanned
on the second or subsequent days, they were imaged on
the same scanner and at the same time of the day as for
their first scan. The mice received an FDG tracer dose
of approximately 200 μCi by infusion through a tail vein
catheter.
Blood glucose measurements
At every scan, blood glucose measurements were taken
twice: once approximately 5 min before and once
shortly after the scan approximately 35 min later. The
glucose value used in calculations is the mean of the
pre- and post-scan measurements. Data were collected
with the commercially available Contour glucometer
(Bayer Healthcare, Tarrytown, NY, USA). Test-retest
reproducibility measurements according to Equation 5
were conducted using this instrument in 20 mice and
showed a coefficient of variation of 3.7%.
Image analysis
Regions of interest [ROIs] were drawn using the image
analysis software IRW from Siemens. For any given
tumor model, all scans for all animals were analyzed by
a single observer following a standard procedure:
Tumor ROIs were defined as voxels exceeding a thresh-
old percentage of the maximal tumor signal measured
in the last 10 min of the scan; this excluded necrotic or
otherwise hypointense regions from the analysis. Mean
signal values from the ROIs were used for analysis.
Image-derived signal from an ROI in the liver was used
as an input function reference region in the Patlak
analysis, a technique described in mice by Green et al.
[21]. This method is well suited to high-resolution
whole-body scans that minimize partial volume artifacts
[20,22], such as those used here.
Time-activity curves and Patlak plots
The Patlak and subsequent statistical analyses were per-
formed with the statistical programming language R
[23]. For each tumor model described in Table 1, exam-
ples of the time-activity curves and the resultant Patlak
plots are presented in Additional file 1 to 11. Ki was
measured from Patlak plots of dynamic FDG-PET data
[15,16,24]. The linear portion of the plot (beginning
approximately 5 min into the time-activity curves) was
used for fitting and visually verified: the correlation
coefficient r2 in each case was at least 0.99.
Kinetic modeling and partial saturation correction
MRGluc was estimated as Ki × [glucose] × LC, where
LC is the lumped kinetic constant (set to unity) and
[glucose] is the blood glucose measurement. Some lit-
erature denotes this form of MRGluc where LC = 1 as
‘MRFDG’ [25,26]; we will use ‘MRGluc’ for its semantic
emphasis on glucose (rather than FDG or glutamate)
uptake. Although the LC scales the absolute value of the
Ki data, it is important to note that the choice of LC has
no bearing on the subsequent analysis of glucose corre-
lation, between-animal coefficient of variation [COV], or
test-retest reproducibility.
MRGluc and its basic dependence on blood glucose
levels were modeled according to Equation 1, a form of





MRGlucMAX is the hypothetical maximal value of glu-
cose uptake rate, approached asymptotically as the
Table 1 Data listed by mouse strains and tumor types
Model Tumor cell line/mouse strain Tissue of origin Number of mice Number of scans
A BT474MI in beige-scid nude Breast 44 76
B HCT116 in athymic nude Colon 124 339
C PC3 in athymic nude Prostate 48 116
D FaDu in C.B.-17 scid Pharynx 20 50
E H292 in C.B.-17 scid Lung 20 40
F H596 in huHGF transgenics Lung 46 81
G 537-MEL in athymic nude Skin 35 52
H A2058 in athymic nude Skin 144 236
I A375 in athymic nude Skin 40 75
J Colo205 in athymic nude Colon 24 58
K H2122 in athymic nude Lung 40 69
Total 585 1,192
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glucose concentration increases to saturating levels. If it
were physically possible, the glucose uptake rate mea-
sured along the horizontal asymptote would be expected
to show zero correlation with the glucose concentration.
The curvature parameter KM is the Michaelis constant
that represents the blood glucose concentration at
which the glucose uptake rate is half the maximal (glu-
cose-saturated) rate.
To see if our data plausibly followed the Michaelis-
Menten model, we transformed the measurements into
the linear double-reciprocal form of Equation 2 and
generated the corresponding Lineweaver-Burk plots





















A further rearrangement allows the computation of






All the data presented in this paper were computed
using Equation 4, and group mean data were calculated
by sample averaging the results for individual animals
within a given study.
Estimation of KM by minimizing the correlation between
blood glucose and MRGlucMAX
We computed estimates of MRGlucMAX with a range of
KM values from 40 to 200 mM and selected the KM that
gave the smallest nonnegative value of the median
Pearson’s correlation coefficient between MRGlucMAX
and [glucose] across all 112 studies. As an exploratory
analysis, we also separately estimated KM for each of the
11 tumor models.
Variability and reproducibility
Between-animal variability was measured as the COV,
calculated as standard error of the estimate divided by
the estimate, and expressed as a percentage. Test-retest
reproducibility statistics were calculated for 19 studies
with the 201 mice that were scanned at day 0 and again
at day 3. This was the most common test-retest interval
in our data. The COVs were calculated using Equation











Both Ki and MRGluc are correlated with blood glucose
levels
In some studies, correlations between blood glucose
levels and the FDG-PET estimates of glucose uptake
rate were readily apparent. Two of these are illustrated
in Figure 1: panel A for Ki and panel B for MRGluc. As
expected, many individual cohorts of 8 to 12 mice were
statistically underpowered to show such a relationship.
More important, and remarkable, was the consistent
presence and strength of this relationship between blood
glucose and tissue uptake rates when seen in the meta-
analysis of our large sample of studies. Figure 2 illus-
trates this using a box plot of Pearson’s correlation coef-
ficients between blood glucose and (A) Ki, and (B)
MRGluc for all 1,192 scans from the 112 studies. The
data are grouped into one box for each of the 11 tumor
models, with the median for each box shown as a hori-
zontal line. Data for each tumor model comprised 4 to
30 studies; the open circles within a box show individual
studies for full disclosure.
Blood glucose levels were negatively correlated with Ki
in 90 studies (Figure 2A). The median correlation coeffi-
cient (dashed line) was -0.4. With MRGluc as the metric
of tumor glucose uptake rate, 104 studies now showed a
positive correlation with a median correlation coefficient
of 0.55 (Figure 2B), indicating that factoring in the glu-
cose did not eliminate the bias, but rather changed it
from negative to positive.
In this meta-analysis of 112 studies, it is possible to
compute for each tumor model confidence interval
around the correlation coefficients reported in Figure 2.
The statistical methodology and results are presented





































































Figure 4 Diagnostic double-reciprocal Lineweaver-Burk plots of
MRGluc versus blood glucose concentration for four different
tumor models. Every point corresponds to an individual mouse.
The line represents the linear regression fit to the data.
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Lineweaver-Burk plots
A preliminary analysis of our data simply looked for
positive correlations between MRGluc and blood glu-
cose levels in the double-reciprocal Lineweaver-Burk
plots that are characteristic of a Michaelis-Menten rela-
tionship [27,28]. Thirteen of the first 20 tumor studies
we examined had some correlation, judging by eye,
encouraging further consideration of the Michaelis-
Menten model in our data. It was also apparent that the
data were inherently noisy such that individual studies
were perhaps underpowered to demonstrate a relation-
ship. No quantitative inferences were drawn from these
analyses, however. Four such studies are shown in Fig-
ure 4.
When KM = 130 mg/dL, MRGluc
MAX shows zero glucose
bias, on average
Figure 2C shows the correlation between MRGlucMAX
and blood glucose when KM = 130 mg/dL. At this value
of KM, the median correlation coefficient for all 112 stu-
dies was practically equal to zero, < 0.0004 (dashed line
in Figure 2C). Of the 112 studies, 55 showed a positive
correlation, 55 showed a negative correlation, and 2 had
practically zero correlation (< 0.003). Increasing values
of KM beyond 130 mg/dL resulted in progressively more
negative median correlation coefficients.
Individual blood glucose often varies between scans
Blood glucose levels recorded at scan time for individual
mice on multiple measurement days are presented in
Figure 3. Each box contains a different cohort of mice
studied on multiple days. Differences in group means
and fluctuations over time are apparent despite consis-
tency of handling.
Between-animal variability
From Figure 5A, we observe that there was typically a
reduction in the COV of MRGlucMAX with respect to
the COV of the same scans quantified using MRGluc.
Most of the points lie below the identity line; 87 of the
112 studies analyzed showed some improvement. The
average reduction in COV was measured as 15.5% from
the value of the fitted regression line slope of 0.845
shown as the dashed line in Figure 5A.
Our hypothesis was that we could reduce variability by
extrapolating the tumor glucose uptake rate measure-
ment to a hypothetical asymptote where glucose is
under saturating conditions, and our data seem to sup-
port this. Mathematically, the improvement in COV
appears to come from the fact that MRGlucMAX is
greater than MRGluc by definition. Specifically, because
KM = 130 mg/dL and the glucose measurements are
near 100 mg/dL, we observe that, on the average,
MRGlucMAX values approximately double those of
MRGluc. The standard error in MRGlucMAX is also
greater than that in MRGluc, but proportionately less
so, and so we get an overall reduction in COV of 15.5%.
Power estimation and sample size calculation
An overall reduction in COV of 15.5% could translate
(statistically equivalently) into either a need for fewer






















































































































































































































Figure 5 COVs in 112 FDG studies of 8 to 12 scans. Each COV was calculated with (MRGlucMAX) or without (MRGluc) partial saturation
correction. For MRGlucMAX, a KM of 130 mg/dL was used. Each open circle represents the COV calculated for one study. (A) Scatter plot of all
112 observations. The solid line represents the identity line. The red dashed line below the identity line represents the linear regression fit to the
data. (B) Box plots showing the COV ratios grouped according to the 11 mouse models employed. The red dashed horizontal line represents the
median of all values.
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effect sizes. Generally speaking, the standard error of
sample means (and of maximum likelihood estimators
in general) is inversely proportional to the square root
of the sample size: this implies that to achieve the same
between-animal COV when using MRGluc would
require an increased sample size of 40% (i.e., 100 × 1/
(1-0.155)2) compared when using MRGlucMAX.
Test-retest reproducibility
For the 19 studies examined, the median test-retest
reproducibility COV results were 22.0% for Ki, 23.1% for
MRGluc, and 20.0% for MRGlucMAX. Figure 6 illustrates
the distribution of COV values for each of the three
PET metrics.
Sensitivity analysis for the between-animal COV as a
function of KM
Varying the value of KM in the range of 40 to 200 mg/
dL did not change the nature of the results: MRGluc-
MAX gave lower between-animal variability than
MRGluc. The reduction in the average COV/KM corre-
spondence was 10% (40 mg/dL), 15% (100 mg/dL),
15.5% (130 mg/dL), and 16% (200 mg/dL).
Discussion
Correlations between blood glucose levels and MRGluc
Figure 2B shows that, in our setting with anesthetized
mice, there is undoubtedly a strong and persistent posi-
tive correlation between blood glucose and MRGluc
across a variety of tumor models and mouse strains. It
is possible to calculate confidence intervals for the cor-
relation coefficients; these reinforce our conclusions
since only one of eleven models had a 95% confidence
interval that included zero (-0.01 to 0.42). These calcula-
tions and results are presented in Additional file 2 for
the interested reader.
Use and applicability of MRGluc
Rigorous methods for estimating the MRGluc utilization
were developed over 30 years ago and continue to be
successfully applied [7,12,26,30,31], not least in tumors
[2,4,17,32-36]. However, capturing the rate of glucose
uptake in the instant of the scan leads to MRGluc
reflecting changes in blood glucose whether or not they
are functionally significant to the tissue. For malignant
tumors, which are highly glucose-addicted, glucose
uptake capacity may well be a more important tissue
characteristic to consider than the glucose uptake rate.
MRGlucMAX reduces glucose bias by emphasizing capa-
city rather than rate.
Fundamental problem with nonlinear regression
estimates of KM and MRGluc
MAX
It may be surprising to some readers that we do not
employ a nonlinear regression model to simultaneously
estimate MRGlucMAX and KM from measurements of Ki
and [glucose]. Although considerable care must be
taken, this approach is known to work [37-39] for enzy-
matic data collected in vitro with minimal statistical
noise in the measurements. However, it proved to be
impossible with our data from living subjects: the objec-
tive function was difficult to optimize and subject to
very large estimation errors. Mathematically, this is due
to maximum likelihood estimates of KM and MRGluc-
MAX being highly linearly codependent, and it requires a
wide range of glucose values to confidently distinguish
the effects of changing KM and changing MRGluc
MAX,
at least when faced with relatively noisy real-world Ki
measurements. This argument is presented in Appendix
1 for the interested reader along with simulations.
Use of a fixed value of KM
The use of an apparent KM value derived in separate
experiments and used within a physiologically reason-
able range has the mathematical advantage that it
reduces the number of parameters we need to estimate
from the scan data and thus avoids the use of under-
powered determinations made on a case-by-case basis.
We used a large sample of studies to determine the KM
at which there was, on average, no net correlation
between MRGlucMAX and blood glucose levels (KM =
130 mg/dL). We regard this as an upper limit; the lower


















Figure 6 Percentage test-retest COV. It was calculated according
to Equation 5 for Ki, MRGluc, and MRGluc
MAX in 19 studies
encompassing 201 mice. Each study consists of 8 to 12 mice
scanned at days 0 and 3.
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measurement can be made with full knowledge of the
extracellular glucose concentration (KM = 40 mg/dL,
[9]).
A biological advantage is that we are better able to fix
the KM as a constant property of a certain tissue or
tumor type under given conditions which are largely
dictated by the discrete nature of the molecular determi-
nants, such as the isotype of the glucose transporter,
GLUT-1 versus GLUT-3, for example.
The importance of tissue glucose and blood glucose
Of particular importance should be how the (mechanisti-
cally relevant) tissue glucose relates to the (conveniently
measured) blood glucose levels [40]. Ideally, we should
know the interstitial glucose concentration in the tumor
microenvironment, and while the relationship between
blood and tissue glucose is of intense interest and active
study, it is still not trivial to measure [41-43]. For normal
tissues, interstitial glucose may be modeled, but in
tumors with all their heterogeneity and variability, this is
likely to remain challenging, and this will likely continue
to present a significant source of variability in data that
depend on tissue glucose but measure blood glucose.
In some tumors, the glucose utilization is so great and
the perfusion so poor that the true tissue glucose may be
close to zero [44], leaving tissue glucose transport far from
being saturated yet also decoupled from blood glucose
levels. We have seen from our data is possible, but not typi-
cal. More common are cases where the FDG uptake rate
does correlate with blood glucose levels, implying some
degree of saturation and thus nonzero tissue glucose levels.
Mathematical expectation of a correlation between Ki ×
[glucose] and [glucose]
Here, we report an empirical correlation between glu-
cose as it is commonly measured (in the blood) and
MRGluc as it is commonly defined and described in the
literature (Ki × [glucose], based on blood glucose mea-
surements). Although it is not widely remarked upon in
the literature, this correlation appears to be almost
inevitable, a natural consequence of the relationship
between Ki, MRGluc, and [glucose]. Given the widely
described result that tissue FDG uptake rates (Ki) and
FDG uptake levels (standardized uptake value [SUV])
are affected by [glucose] [2-6,45-48], truly incredible cir-
cumstances must prevail to have zero correlation
between MRGlu and [glucose] under all circumstances.
A more extensive mathematical analysis of this problem
is presented for the interested reader in the Appendix 2.
Applicability of KM values across multiple tumor types
Model-specific KM values might be expected to have
some benefit and were tested as an exploratory measure.
They made it possible to bring the blood glucose
correlation with MRGlucMAX close to zero for each
tumor model independently. However, there was no
additional improvement in the between-animal variabil-
ity. Employing a global value of 130 mg/dL seemed ade-
quate for these exploratory studies given that the
benefits of using MRGlucMAX are not critically depen-
dent on using a precise value of KM.
Alternative linear regression method for estimation of
MRGlucMAX with a fixed KM
Having adopted the use of a fixed value for KM, we note
that a least-squares linear regression method to compute
MRGlucMAX is readily apparent from Equation 3 by plot-
ting Ki as a function of (1/(KM + [glucose]), giving a
straight line with MRGlucMAX as the slope when the
regression line is forced through the origin. Estimation of
the group mean by linear regression may perform better
than averaging individual values (c.f., Section II.5 in the
book by Christensen [49]). However, when we tested this
alternative calculation, we found that it made no appreci-
able difference to the results. We note that linear regres-
sion should offer the greatest benefit where the data
contain a wide spread of glucose concentrations; as we
noted above, this is not the case for our living-subject data
with its relatively narrow range of physiological blood glu-
cose values and relatively high noise level.
Variability and statistical power of MRGlucMAX compared
to MRGluc
As noted, a 40% increase in sample size would be
required to achieve a 15.5% reduction in COV. How-
ever, translating a reduction in COV to improve statisti-
cal power requires additional assumptions, e.g.,
regarding the potential treatment effect [50]. To make a
preliminary estimate, we assume that the relative treat-
ment effect is the same for MRGlucMAX and MRGluc
when expressed as a percentage change from baseline (a
conservative assumption since MRGlucMAX is an asymp-
tote). In this case, the reduction in the required sample
size while maintaining the same error rates (i.e., the
same statistical power) is 28.6% (equal to 100 × (1-(1-
0.155)2)) (see Equation 2 in van Belle and Martin [50]).
The actual sample size savings achieved in practice are
likely to be smaller than this because assumptions will
not hold exactly. In particular, glucose uptake is only
approximated by Michaelis-Menten kinetics; KM is not
known exactly; and the error distribution may be neither
Gaussian nor perfectly homoscedastic.
No doubt there are many sources of physiological
noise contributing to the total observed variability in Ki
[51], and blood glucose may be only a small part of
that. Nevertheless, a 15.5% reduction in between-animal
COV is not trivial and could well become important
over the course of many studies or in marginal cases.
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Also, this improvement should not be considered in iso-
lation, but seen as one step in the evolution of PET
methodology over the years.
Glucose normalization and bias
Although biologically appealing, mixed results have
come from previous studies of linear glucose normaliza-
tions applied to FDG-PET data [3-5]. Multiplying Ki by
blood glucose (or normalized glucose, i.e., [glucose]/100
mg/dL) did not eliminate bias in our data. Some have
found that this normalization actually increased variabil-
ity and was unhelpful [8,52,53], possibly because of the
noise introduced by the glucose assay. However, glucose
bias was significantly reduced with the nonlinear
MRGlucMAX function, while simultaneously achieving
reductions in between-animal and test-retest COVs
compared to both Ki and MRGluc. This is very encoura-
ging and warrants further investigation.
Other nonlinear glucose corrections
Given the significant biological noise that remains in
FDG-PET data even after various corrections are
applied, other line equations that approximate the
Michaelis-Menten equation should fit the data and give
broadly similar bias reductions and improvements in
glucose-derived variability. For example, Wong et al.
have demonstrated that using a square-root function of
the glucose concentration allowed their clinical SUV
data to better classify indolent and aggressive lympho-
mas [54]. They also suggested, referring to Langen et al.
[2], that this correction would not be necessary with
dynamic scans quantified with MRGluc.
Applicability to SUV data
Our preliminary observations confirm that tumor SUV
values correlate highly with our Ki data, showing a nega-
tive correlation with blood glucose across hundreds of
mice and dozens of studies. However, our SUV values
were derived from time-activity curves at no more than
30 min after injection of FDG, and with only 5 min of
acquisition time, making them statistically noisy com-
pared to purposeful SUV data. We expect that partial
saturation correction will have similar benefits with
SUV data, but more appropriate experimental data will
be required before this can be properly explored. How-
ever, applying the square root of glucose SUV correction
of Wong et al. [54] to our tumor data did reduce glu-
cose bias and variability compared to MRGluc, almost
as much as MRGlucMAX. The converse should also be
true, suggesting that multiplying SUV by (KM + [glu-
cose]) would be effective in the clinical lymphoma set-
ting, while the mechanistic foundation of this correction
may make it possible to rationally optimize KM in differ-
ent tissues or tumor types.
Outliers and blood glucose changes during the scan
Individual outliers often exhibited large differences
between their pre-scan and post-scan blood glucose
levels. We tested some exclusion criteria which censored
out data from scans where there had been a 75% or
greater change in blood glucose level during the course
of the scan. This helped reduce the between-animal
variability in some studies. However, a more attractive
alternative may be to track and account for the changes
in blood glucose occurring during a scan as proposed by
Dunn et al. [55]. It would be interesting to evaluate a
combination of partial saturation correction and the
method of Dunn et al. [55] to better account for both
between-scan and intra-scan blood glucose changes.
Conclusions
Measured in a very large sample of 1,192 nonclinical
dynamic FDG-PET scans, it was clear that the rate of
tumor glucose uptake estimated by MRGluc was, in
most studies, positively correlated with blood glucose
levels. This gave an unwanted bias and additional varia-
bility in our estimates of tumor glucose uptake rates.
By assuming a Michaelis-Menten relationship, the
simple use of KM + [glucose] in place of [glucose] as the
glucose correction factor had several benefits: the
hypothetical glucose-saturated MRGlucMAX was less
correlated with blood glucose, had lower between-ani-
mal variability, and had lower test-retest variability com-
pared to MRGluc.
Future directions
This reduced bias and reduced variability may translate
into a significant reduction in sample size (up to 28%)
for nonclinical treatment studies. Further performance
comparisons of MRGluc and MRGlucMAX applied to
detect confirmed treatment responses in our nonclinical
tumor models have been completed and will be
described separately.
It will be very interesting, and straightforward, to see
if these findings can be translated to studies of clinical
trial data where saturation-corrected SUV data could be
calculated by multiplying SUV by (100 mg/dL + [glu-
cose]), rather than the more commonly reported glu-
cose-normalized SUV employing ([glucose]/100 mg/dL).
In the clinical trial setting, even modest reductions in
variability can translate to tangible savings in money,
time, and patient enrollment.
Appendix 1
On the problem of linearly dependent ML estimates of
Km and Vmax from noisy Michaelis-Menten observations
If an adequate probabilistic framework can be specified
for a sample data set, maximum likelihood [ML] typi-
cally provides an efficient approach for parameter
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estimation. Equivalently, for data which are conditionally
Gaussian-distributed, one may also use nonlinear least
squares. However, due to the functional form of the
Michaelis-Menten [MM] relationship, Km and Vmax are
not uniquely estimable (from each other) from noisy
MM observations. This problem is further exacerbated
when the MM process is observed in a narrow glucose
range (as is the case in our work). The problem can be
understood by studying the information matrix for Km
and Vmax, but we use a first-order expansion of the ML
score function to heuristically verify that the ML para-
meter estimates of Km and Vmax are strongly co-linear.
Let the true values of Km and Vmax be given by Ko and
Vo, respectively. For j = 1,...,n, let
Kji = Vo/(Ko + [glc]
j) + εj be the j:th observed rate con-
stant where εj is independently sampled from a zero-
mean Gaussian distribution with standard deviation s.




Kji − Vmax/(Km + [glc]j)
)2
be the ML score function to be minimized. The ML
estimates are given by
{Vˆmax, Kˆm, σˆ } = min
Vmax,Km,σ
S(Vmax,Km, σ ).
We note that estimation of s does not affect estimates
of Vmax and Km, and its consideration is henceforth
eschewed.
For reasonably large sample sizes, at convergence, the





2 − 2εj/(Ko + [glc]j)[(Vˆmax − Vo) − Vo/(Ko + [glc]j)(Kˆm − Ko)]
+1/(Ko + [glc]j)
2
[(Vˆmax − Vo)− Vo/(Ko + [glc]j)(Kˆm − Ko)]2.
Taking expectations over the noise process, εj yields
that on the average, the score is minimized approxi-
mately when (Vˆmax − Vo) = Vo/(Ko + [m.glc])(Kˆm − Ko) ,
where [m.glc] represents the mean glucose measure-
ment. The result holds when the glucose measurements
have low spread but can be shown to hold approxi-
mately even as the spread around [m.glc] increases.
Thus, Vˆmax is linear in Kˆm with a slope equal to Vo/(Ko
+[m.glc]).
To illustrate, we ran 400 simulations with the follow-
ing parameters: Vmax = Vo = 40, Km = Ko = 100, s =
.025, where glucose was randomly sampled from a
Gaussian distribution with the mean [m.glc] = 100 and
standard deviation of 20. Each such simulation used a
total of n = 20 observations. These parameter settings
were chosen to simulate data which closely mimics the
previously presented data. The R function nls() was used
for ML estimation. Figure 7 shows pairs of estimates of
Vmax (i.e., Vˆmax on the y-axis) and Km ( Kˆm on the x-
axis) from these 400 simulations. As can be seen, the
ML estimates are highly linearly dependent and have a
slope of 0.2072, very near to that derived by Vo/(Ko+[m.
glc]) = .20. Further, the sample correlation in this plot is
.995, indicating that estimates are not uniquely identifi-
able from the data.
Although slightly improved, simulations verify that the
above problem persists even as the spread in [glc] is
greatly increased. Figure 8 sheds some intuition on the
overall problem. Along with the black MM curve used















Figure 7 Highly linearly dependent ML estimates of Kˆm and
Vˆmax from perfect model simulations with {Km = 100, Vmax =
40, s = .025}.





















Different Combinations of Km and Vmax
Figure 8 Plotted sample data can be expected to fit any of the
five depicted MM models.
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to generate 20 sample data points (denoted by black ‘x’)
are the MM curves for four other parameter settings
(see figure legend for parameter values). As is evident,
the sample data cannot be expected to ‘choose’ effi-
ciently among the depicted candidate models as
increases in Km are ‘traded’ for increases (and vice
versa) in Vmax at the rate of .2. This estimation issue
remains even as the sample size is increased albeit with
decreasing overall sample variability at a rate of 1/sqrt
(n).
Appendix 2
On the correlation between MRgluc and [glc]
As noted, several authors have described studies where
the observed rates Ki were negatively correlated with the
glucose measurements [glc]. We show that when such a
negative correlation exists, the correlation between
MRgluc, defined as the product between Ki and [glc],
and [glc] cannot uniformly equal zero. Indeed, lack of
correlation occurs but in a few special cases.
Since Ki > 0 and [glc] > 0 are negatively correlated,
there exist constants a > 0 and b < 0 such that the
form Ki ≈ a + b[glc] + ε describes the correlation
between Ki and [glc]. Here, ε is a zero-mean error pro-
cess independent of [glc] with variance σ 2ε . Then, with
μkg denoting the k:th raw moment of [glc] and with σ
2
g
its variance, straightforward algebra shows that the cov-
ariance between MRgluc and [glc] equals
cov(MRgluc, [glc]) = ασ 2g + β(μ
3
g − μ2gμg).
Thus, for cov(MRgluc, [glc]) = 0, we must have
ασ 2g = −β(μ3g − μ2gμg) or α/β = (μ2gμg − μ3g )/σ 2g . This
equality can clearly not hold uniformly across a broad
range of realistic parameter choices of {α,β ,μg,μ2g ,μ3g } .
We illustrate the result by simulations. Our setting
assumes that Ki follows the MM form with constants
Km and Vmax and that the observed rate is corrupted by
noise. That is, Ki = Vmax/(Km + [glc]) + ε, where ε is the
random Gaussian with zero-mean and standard devia-
tion s. As is common, we further assume that the rate
constant is observed (sampled) in a glucose range
between 60 and 140. We note that when Ki is observed
in a limited range around some glucose midpoint [m.
glc], Ki ≈ (Vmax/(Km + [m.glc])+([m.glc]Vmax)/(Km + [m.
glc])2)-Vmax/(Km + [m.glc])
2[glc] + ε, i.e., Ki is approxi-
mately linear in [glc].
The left panel in Figure 9 shows 400 simulated obser-
vations drawn from a MM model with Vmax = 40, Km =
100, s = .025, where glucose was randomly sampled
from a Gaussian distribution with a mean of 100 and a
standard deviation of 15. As can be seen, in the sampled
range, Ki is approximately linear in [glc]. The right panel
shows a scatter plot of [glc] vs. MRgluc. Consistent with
our derivations, the sample correlations in the two plots
are -.48 and .53, respectively. For the chosen parameter
choices and glucose distribution, based on the above
arguments, the sample correlation between [glc] and
MRgluc should be near to its theoretically predicted
value of .51. (For this data, the sample correlation
between [glc] and MRglucMAX = Ki(Km + [glc]) is .01.)

































Figure 9 Scatter plots of [glc] vs. Ki (left) and [glc] vs. MRgluc (right). The left panel also shows the underlying MM process (dashed black
line) from which the data was sampled, along with theoretical (red solid) and fitted (black solid) regression lines.
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Additional material
Additional file 1: ROI data and corresponding Patlak plots from
FDG-PET scans in each of the 11 tumor models A to K discussed in
the text (see Table 1). In each plot, the data from one cohort (n = 14
to 36) of essentially identical mice are superimposed. Left, in red: the
liver-derived input function; center, in blue: the tumor; right, in gray: the
Patlak plot.
Additional file 2: Confidence intervals for correlations between PET
metrics and blood glucose. To obtain the 95% confidence limits for
Pearson’s correlation coefficient (r), the Fisher transformation was applied
to the sample correlation coefficients.
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